These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 9713969)

  • 21. Phase I pharmacokinetic and pharmacodynamic analysis of unconjugated soy isoflavones administered to individuals with cancer.
    Takimoto CH; Glover K; Huang X; Hayes SA; Gallot L; Quinn M; Jovanovic BD; Shapiro A; Hernandez L; Goetz A; Llorens V; Lieberman R; Crowell JA; Poisson BA; Bergan RC
    Cancer Epidemiol Biomarkers Prev; 2003 Nov; 12(11 Pt 1):1213-21. PubMed ID: 14652284
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Favorable pharmacodynamic features and superior anti-leukemic activity of B43 (anti-CD19) immunotoxins containing two pokeweed antiviral protein molecules covalently linked to each monoclonal antibody molecule.
    Myers DE; Yanishevski Y; Masson E; Irvin JD; Evans WE; Uckun FM
    Leuk Lymphoma; 1995 Jun; 18(1-2):93-102. PubMed ID: 8580835
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies.
    Blanc V; Bousseau A; Caron A; Carrez C; Lutz RJ; Lambert JM
    Clin Cancer Res; 2011 Oct; 17(20):6448-58. PubMed ID: 22003072
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of temozolomide in a SCID mouse model of human B-cell precursor leukemia.
    Messinger Y; Reaman GH; Ek O; Uckun FM
    Leuk Lymphoma; 1999 Apr; 33(3-4):289-93. PubMed ID: 10221508
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Eradication of CD19+ leukemia by targeted calicheamicin θ.
    Bernt KM; Prokop A; Huebener N; Gaedicke G; Wrasidlo W; Lode HN
    Bioconjug Chem; 2009 Aug; 20(8):1587-94. PubMed ID: 19572629
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II clinical trial of bolus infusion anti-B4 blocked ricin immunoconjugate in patients with relapsed B-cell non-Hodgkin's lymphoma.
    Multani PS; O'Day S; Nadler LM; Grossbard ML
    Clin Cancer Res; 1998 Nov; 4(11):2599-604. PubMed ID: 9829722
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of human B-cell precursor leukemia in SCID mice using a combination of the investigational biotherapeutic agent B43-PAP with cytosine arabinoside.
    Messinger Y; Yanishevski Y; Avramis VI; Ek O; Chelstrom LM; Gunther R; Myers DE; Irvin JD; Evans W; Uckun FM
    Clin Cancer Res; 1996 Sep; 2(9):1533-42. PubMed ID: 9816330
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Murine toxicology and pharmacokinetics of novel retinoic acid metabolism blocking agents.
    Patel JB; Khandelwal A; Chopra P; Handratta VD; Njar VC
    Cancer Chemother Pharmacol; 2007 Nov; 60(6):899-905. PubMed ID: 17345084
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rational design of an immunoconjugate for selective knock-down of leukemia-specific E2A-PBX1 fusion gene expression in human Pre-B leukemia.
    Uckun FM; Qazi S; Dibirdik I; Myers DE
    Integr Biol (Camb); 2013 Jan; 5(1):122-32. PubMed ID: 22990208
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vivo pharmacokinetic features, toxicity profile, and chemosensitizing activity of alpha-cyano-beta-hydroxy-beta- methyl-N-(2,5-dibromophenyl)propenamide (LFM-A13), a novel antileukemic agent targeting Bruton's tyrosine kinase.
    Uckun FM; Zheng Y; Cetkovic-Cvrlje M; Vassilev A; Lisowski E; Waurzyniak B; Chen H; Carpenter R; Chen CL
    Clin Cancer Res; 2002 May; 8(5):1224-33. PubMed ID: 12006542
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preclinical toxicity and pharmacokinetics of the Bruton's tyrosine kinase-targeting anti-leukemic drug candidate, alpha-cyano-beta-hydroxy-beta-methyl-N- (2,5-dibromophenyl) propenamide (LFM-A13).
    Uckun FM; Tibbles H; Venkatachalam T; DuMez D; Erbeck D
    Arzneimittelforschung; 2007; 57(1):31-46. PubMed ID: 17341007
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical characteristics and pharmacokinetics of purified soy isoflavones: single-dose administration to healthy men.
    Busby MG; Jeffcoat AR; Bloedon LT; Koch MA; Black T; Dix KJ; Heizer WD; Thomas BF; Hill JM; Crowell JA; Zeisel SH
    Am J Clin Nutr; 2002 Jan; 75(1):126-36. PubMed ID: 11756070
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vivo toxicity and pharmacokinetic features of the janus kinase 3 inhibitor WHI-P131 [4-(4'hydroxyphenyl)-amino-6,7- dimethoxyquinazoline.
    Uckun FM; Ek O; Liu XP; Chen CL
    Clin Cancer Res; 1999 Oct; 5(10):2954-62. PubMed ID: 10537365
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates.
    Allen TM; Mumbengegwi DR; Charrois GJ
    Clin Cancer Res; 2005 May; 11(9):3567-73. PubMed ID: 15867261
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cisplatin-induced antitumor activity is potentiated by the soy isoflavone genistein in BxPC-3 pancreatic tumor xenografts.
    Mohammad RM; Banerjee S; Li Y; Aboukameel A; Kucuk O; Sarkar FH
    Cancer; 2006 Mar; 106(6):1260-8. PubMed ID: 16475211
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys.
    Sapra P; Stein R; Pickett J; Qu Z; Govindan SV; Cardillo TM; Hansen HJ; Horak ID; Griffiths GL; Goldenberg DM
    Clin Cancer Res; 2005 Jul; 11(14):5257-64. PubMed ID: 16033844
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
    Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
    MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NTP toxicity report of reproductive dose range-finding study of Genistein (CAS No. 446-72-0) administered in feed to Sprague-Dawley rats.
    Delclos KB; Newbold R
    Toxic Rep Ser; 2007 Nov; (79):1-C2. PubMed ID: 18685712
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Toxicity, biological activity, and pharmacokinetics of TXU (anti-CD7)-pokeweed antiviral protein in chimpanzees and adult patients infected with human immunodeficiency virus.
    Uckun FM; Bellomy K; O'Neill K; Messinger Y; Johnson T; Chen CL
    J Pharmacol Exp Ther; 1999 Dec; 291(3):1301-7. PubMed ID: 10565855
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined cetuximab and genistein treatment shows additive anti-cancer effect on oral squamous cell carcinoma.
    Park SJ; Kim MJ; Kim YK; Kim SM; Park JY; Myoung H
    Cancer Lett; 2010 Jun; 292(1):54-63. PubMed ID: 19959278
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.